Titan Pharmaceuticals Inc
TTNP
$5.60
Closing
▲0.18%
1D
▼-32.12%
YTD
TTNP
BBG001S72H65
Market cap
$5.06M
52 week high
$14.78
52 week low
$4.47
Volume
4,304
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$5.06M
Analysts' Rating
-
Price Target (Mean)
0.00
Total Analysts
0
P/E
Operating Margin
0.00%
Beta
1.11
Revenue Growth
-100.00%
52 week high
$14.78
52 week low
$4.47
Div. Yield
%
EPS Growth
0.00
Company Profile
Titan Pharmaceuticals, Inc. is a pharmaceutical company. The Company is focused on developing therapeutics utilizing the proprietary long-term drug delivery platform, ProNeura, for the treatment of select chronic diseases. ProNeura offers continuous drug delivery and consists of a small, semi-rigid, flexible implant made from a mixture of ethylene-vinyl acetate (EVA) and a drug substance. The resulting product is a solid matrix implant that is placed subdermally, normally in the inside part of the upper arm, in a brief procedure using a local anesthetic and is removed in a similar manner at the end of the treatment period. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus. Its product development programs are in non-clinical stages of development.
